BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25814085)

  • 1. Discontinuation of tyrosine kinase therapy in CML.
    Mahon FX
    Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Rea D
    Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interferon-alpha revival in CML.
    Talpaz M; Mercer J; Hehlmann R
    Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the European LeukemiaNet recommendations for the management of CML.
    Baccarani M; Castagnetti F; Gugliotta G; Rosti G
    Ann Hematol; 2015 Apr; 94 Suppl 2():S141-7. PubMed ID: 25814080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
    Erba HP
    Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 8. Response-related predictors of survival in CML.
    Hanfstein B; Müller MC; Hochhaus A
    Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of first-line chronic myelogenous leukemia treatment.
    Fava C; Rege-Cambrin G; Saglio G
    Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing pregnancy in chronic myeloid leukaemia.
    Palani R; Milojkovic D; Apperley JF
    Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of chronic myeloid leukemia in blast crisis.
    Saußele S; Silver RT
    Ann Hematol; 2015 Apr; 94 Suppl 2():S159-65. PubMed ID: 25814082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
    Bansal A; Radich J
    Curr Opin Hematol; 2016 Mar; 23(2):115-20. PubMed ID: 26825700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
    Frankfurt O; Licht JD
    Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
    Turkina AG; Chelysheva EIu
    Ter Arkh; 2013; 85(7):4-9. PubMed ID: 24137941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.